Inhaled beclomethasone versus placebo in the treatment of, asymptomatic or mild to moderate COVID-19 infection to prevent progression to severe disease in a cohort of Sri Lankans: a randomized trial
- Conditions
- COVID19
- Registration Number
- SLCTR/2021/017
- Lead Sponsor
- Chamila Mettananda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Not specified
- Target Recruitment
- Not specified
All consenting males and females above 18 years of age with asymptomatic disease on admission or mild/moderate COVID19 (according to National Institutes of Health criteria) within the first 7 days of symptom onset admitted to District Hospital Kandana with a positive SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test).
1. Patients refusing consent
2. Age < 18 years
3. Recent use (within 14 days) of inhaled or systemic glucocorticoids
4. Contraindication to beclomethasone
5. Inability to use inhalation device without assistance
6. Patients suffering from psychiatric illnesses lacking the insight to partake fully
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.